Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE

Overview of attention for article published in Journal of Clinical Oncology, May 2025

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)

Mentioned by

twitter: 6 X users
facebook: 1 Facebook page

bluesky: 1 Bluesky user

Readers on

mendeley: 10 Mendeley

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 11,438 followers.

Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE https://t.co/AxbgkvrVlj #Cancer

Kudos 👏🏽 to @GistLab on @JCO_ASCO 📑 @OHSUKnight #endcancer https://t.co/s0XFCpM2TG

#J_Clin_Oncol IF:42.1 Phase III RCT (INTRIGUE, n=453). Ripretinib vs sunitinib for advanced GIST showed similar OS (35.5 vs 31.5mo) and 2nd PFS (7.7 vs 7.4mo). PMID:40408605 https://t.co/xbKPfmErnN

RT @tuttsakhil: Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Ove…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.